Corneal Disorders

The cornea is the very outer layer of the eye. Corneal disorders might include refractive errors, allergies, injuries, and more.

Programs + Services

Ophthalmology (New England Eye Center)

Ophthalmology (New England Eye Center) at Tufts Medical Center in Boston specializes in the testing and treatment of all types of eye diseases and visual problems.
More information about programs and services

Research + Clinical Trials

A 12-week parallel group, randomized, placebo-controlled, double-blinded, multi-center study to evaluate efficacy and safety of 2 concentrations of SAF312 eye drops (5mg/ml and 15mg/ml) used twice-daily in the treatment of post-operative corneal induced chronic pain (CICP) following Photorefractive Keratectomy (PRK) or Laser-assisted in Situ Keratomileusis (LASIK) surgeries

The study is designed to demonstrate the safety and efficacy of two dose concentrations of SAF312 eye drops (dose 1 [5 mg/ml] and dose 2 [15 mg/ml]) in subjects with chronic induced corneal pain (CICP) persisting at least for 4 months after refractive surgery and chronicity confirmed during the observational period. The study will also determine the optimal dose to carry forward for further development.
More information about research and clinical trials

A Multi-center, Randomized, Double-masked, Vehicle-controlled, Parallel-group, Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Stage 2 and 3 Neurotrophic Keratitis Subjects

This study will enroll subjects with stage 2 or 3 neurotrophic keratitis. Subjects will be randomized in a 1:1 ratio to the CSB-001 investigational treatment arm or vehicle control arm. All subjects will dose with the randomized treatment four times daily for 8 weeks (controlled treatment phase). During the controlled treatment phase, subjects will return to the clinic weekly from Day 0 to Week 8, and again at Week 10. Subjects randomized to the vehicle arm who are not healed will have the opportunity to participate in an open-label uncontrolled treatment phase.
More information about research and clinical trials

A phase 2B, multi-center, randomized, double-blind, placebo-controlled study with Open-Label Extension to Evaluate the Safety and Efficacy of ST266 Eye Drops in the Treatment of Persistent Corneal Epithelial Defects

The primary objective is to determine the efficacy of ST266 eye drops in healing persistent epithelial defects (PED). After 8 weeks of randomized, double-blind treatment, non-healers will enter into an additional 8-week open-label ST266 treatment period. All patients will be followed for 3-months post-treatment for monitoring of safety and maintenance of re-epithelialization.
More information about research and clinical trials

Assessing the Efficacy of Intranasal Neurostimulation in Ameliorating Symptoms of Neuropathic Corneal Pain 

Patients that suffered from neuropathic pain or photoallodynia, reported immediate relief of pain after use of TrueTear® intranasal neurostimulator (ITN). We propose a pilot study for treatment of neuropathic corneal pain (NCP) with ITN with the following specific aims: 

• To elucidate the efficacy of ITN in ameliorating pain among neuropathic corneal patients.
• To elucidate the safety, efficacy, longevity of ITN in ameliorating pain among neuropathic corneal patients during a 90-day period with daily use.
• o assess quality of life changes by treating neuropathic corneal pain with ITN during a 90-day period with daily use.